Page 2,709«..1020..2,7082,7092,7102,711..2,7202,730..»

International Stem Cell Corporation Reports Reaching Milestone in Its Cornea Program

Posted: June 28, 2012 at 6:21 pm

CARLSBAD, CA--(Marketwire -06/28/12)- International Stem Cell Corporation (ISCO) http://www.internationalstemcell.com today announced that its Research and Development team has advanced its program to create a functional and transplantable human cornea by developing a new method to derive corneal endothelium-like cells from human pluripotent stem cells.

This work represents a significant step towards the creation of complete cornea tissue that can be used for transplantation and supports prior data showing indications of corneal endothelium generated by ISCO's collaborators at Sankara Nethralaya Eye Hospital, India. Such cells by themselves may potentially promote wound healing and regeneration of the cornea and therefore could be used as a standalone medical treatment.

Development and commercialization of ISCO's stem cell-derived cornea tissue along with manufacturing of Lifeline Cell Technology's media and cellular products are the foundation for our expansion to the Asian markets and for clinical collaboration with Indian biomedical organizations including Sankara Nethralaya Eye Hospital and All-India Institute for Medical Sciences.

Asia represents a huge potential growth market for ISCO's Cornea program. For example, in India alone there are more than 4 million people suffering from corneal vision impairment with limited access to corneal tissue. ISCO's intention is to work with our clinical affiliate in India to meet this healthcare demand.

Dr. Ruslan Semechkin, Vice President of Research & Development, commented: "This new method not only brings our cornea program closer to clinical use, but it also gives us additional licensing opportunities. We have made good progress towards our goal of creating usable corneas, however the additional work, necessary to prove that these endothelium-like cells can be fully functional, will be done in conjunction with our collaborators."

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at http://www.internationalstemcell.com or follow us on Twitter @intlstemcell.

To receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

Forward-Looking StatementsStatements pertaining to anticipated developments, the potential benefits of research programs and products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

More here:
International Stem Cell Corporation Reports Reaching Milestone in Its Cornea Program

Posted in Stem Cell Research | Comments Off on International Stem Cell Corporation Reports Reaching Milestone in Its Cornea Program

Turning skin cells into brain cells

Posted: June 28, 2012 at 5:18 pm

Public release date: 28-Jun-2012 [ | E-mail | Share ]

Contact: Stephanie Desmon sdesmon1@jhmi.edu 410-955-8665 Johns Hopkins Medical Institutions

Johns Hopkins researchers, working with an international consortium, say they have generated stem cells from skin cells from a person with a severe, early-onset form of Huntington's disease (HD), and turned them into neurons that degenerate just like those affected by the fatal inherited disorder.

By creating "HD in a dish," the researchers say they have taken a major step forward in efforts to better understand what disables and kills the cells in people with HD, and to test the effects of potential drug therapies on cells that are otherwise locked deep in the brain.

Although the autosomal dominant gene mutation responsible for HD was identified in 1993, there is no cure. No treatments are available even to slow its progression.

The research, published in the journal Cell Stem Cell, is the work of a Huntington's Disease iPSC Consortium, including scientists from the Johns Hopkins University School of Medicine in Baltimore, Cedars-Sinai Medical Center in Los Angeles and the University of California, Irvine, as well as six other groups. The consortium studied several other HD cell lines and control cell lines in order to make sure results were consistent and reproducible in different labs.

The general midlife onset and progressive brain damage of HD are especially cruel, slowly causing jerky, twitch-like movements, lack of muscle control, psychiatric disorders and dementia, and eventually death. In some cases (as in the patient who donated the material for the cells made at Johns Hopkins), the disease can strike earlier, even in childhood.

"Having these cells will allow us to screen for therapeutics in a way we haven't been able to before in Huntington's disease," says Christopher A. Ross, M.D., Ph.D., a professor of psychiatry and behavioral sciences, neurology, pharmacology and neuroscience at the Johns Hopkins University School of Medicine and one of the study's lead researchers. "For the first time, we will be able to study how drugs work on human HD neurons and hopefully take those findings directly to the clinic."

Ross and his team, as well as other collaborators at Johns Hopkins and Emory University, are already testing small molecules for the ability to block HD iPSC degeneration. These small molecules have the potential to be developed into novel drugs for HD.

The ability to generate from stem cells the same neurons found in Huntington's disease may also have implications for similar research in other neurodegenerative diseases such as Alzheimer's and Parkinson's.

Read this article:
Turning skin cells into brain cells

Posted in Stem Cells | Comments Off on Turning skin cells into brain cells

Taking the fate of stem cells in hand: RUB researchers generate immature nerve cells

Posted: June 28, 2012 at 5:18 pm

Public release date: 28-Jun-2012 [ | E-mail | Share ]

Contact: Dr. Stefan Wiese stefan.wiese@rub.de 49-234-322-2041 Ruhr-University Bochum

RUB biologists have deliberately transformed stem cells from the spinal cord of mice into immature nerve cells. This was achieved by changing the cellular environment, known as the extracellular matrix, using the substance sodium chlorate. Via sugar side chains, the extracellular matrix determines which cell type a stem cell can generate. "Influencing precursor cells pharmacologically so that they transform into a particular type of cell can help in cell replacement therapies in future" says Prof. Dr. Stefan Wiese, head of the Molecular Cell Biology work group. "Therapies, for example, for Parkinson's, multiple sclerosis or amyotrophic lateral sclerosis could then become more efficient." The team describes its findings in Neural Development.

Sulphate determines the fate of stem cells

Sodium chlorate acts on metabolism enzymes in the cell which attach sulphate groups to proteins. If these sulphates are not installed, the cell continues to form proteins for the extracellular matrix, but with modified sugar side chains. These chains in turn send out signals that define the fate of the stem cells. Stem cells can not only develop into nerve cells, but also form astrocytes or oligodendrocytes, which are, for instance, responsible for the mineral balance of the nerve cells or which form their insulation layer. What happens to the stem cells if the sulphate pattern is changed by sodium chlorate was examined by Dr. Michael Karus and his colleagues.

Positive side effects: nerve cells remain immature

The RUB-laboratories of Prof. Dr. Stefan Wiese, Prof. Dr. Andreas Faissner and Prof. Dr. Irmgard Dietzel-Meyer collaborated for the study. Using antibodies, the researchers showed that cells which they had treated with sodium chlorate developed into nerve cells. They also analysed the flow of sodium ions into the cells. The result: treated cells showed a lower sodium current than mature nerve cells. Sodium chlorate thus favours the development of stem cells into nerve cells, but, at the same time, also inhibits the maturation - a positive side effect, as Wiese explains: "If sodium chlorate stops the nerve cells in an early developmental phase, this could enable them to integrate into the nervous system following a transplant better than mature nerve cells would do."

###

Bibliographic record

M. Karus, S. Samtleben, C. Busse, T. Tsai, I.D. Dietzel, A. Faissner, S. Wiese (2012): Normal sulphation levels regulate spinal cord neural precursor cell proliferation and differentiation, Neural Development, doi: 10.1186/1749-8104-7-20

See the original post here:
Taking the fate of stem cells in hand: RUB researchers generate immature nerve cells

Posted in Stem Cells | Comments Off on Taking the fate of stem cells in hand: RUB researchers generate immature nerve cells

Stem cells may help reverse diabetes

Posted: June 28, 2012 at 5:18 pm

Washington, June 28 : In a new study, researchers have successfully reversed diabetes in mice using stem cells, thereby paving the way for a breakthrough treatment for a disease that affects millions worldwide.

The research by Timothy Kieffer, from University of British Columbia in collaboration with scientists from the New Jersey-based BetaLogics, is the first to show that human stem cell transplants can successfully restore insulin production and reverse diabetes in mice.

Crucially, they re-created the "feedback loop" that enables insulin levels to automatically rise or fall based on blood glucose levels.

After the stem cell transplant, the diabetic mice were weaned off insulin, a procedure designed to mimic human clinical conditions.

Three to four months later, the mice were able to maintain healthy blood sugar levels even when being fed large quantities of sugar.

Transplanted cells removed from the mice after several months had all the markings of normal insulin-producing pancreatic cells.

"We are very excited by these findings, but additional research is needed before this approach can be tested clinically in humans," Kieffer said.

"The studies were performed in diabetic mice that lacked a properly functioning immune system that would otherwise have rejected the cells. We now need to identify a suitable way of protecting the cells from immune attack so that the transplant can ultimately be performed in the absence of any immunosuppression," Kieffer added.

The study has been recently published online in Diabetes. (ANI)

More from health-news:

Read the original post:
Stem cells may help reverse diabetes

Posted in Stem Cells | Comments Off on Stem cells may help reverse diabetes

Cedars-Sinai researchers, with stem cells and global colleagues, develop Huntingtons research tool

Posted: June 28, 2012 at 5:18 pm

Public release date: 28-Jun-2012 [ | E-mail | Share ]

Contact: Nicole White nicole.white@cshs.org 310-423-5215 Cedars-Sinai Medical Center

LOS ANGELES (EMBARGOED UNTIL NOON EDT ON JUNE 28, 2012) Cedars-Sinai scientists have joined with expert colleagues around the globe in using stem cells to develop a laboratory model for Huntington's disease, allowing researchers for the first time to test directly on human cells potential treatments for this fatal, inherited disorder.

As explained in a paper published June 28 on the Cell Stem Cell website and scheduled for print in the journal's Aug. 3 issue, scientists at Cedars-Sinai's Regenerative Medicine Institute and the University of Wisconsin took skin cells from patients with Huntington's disease and reprogrammed them into powerful stem cells; these were then made into the nervous system cells affected by the disease. Seven laboratories around the world collaborated to demonstrate the cells had hallmarks of Huntington's.

"This Huntington's 'disease in a dish' will enable us for the first time to test therapies on human Huntington's disease neurons," said Clive Svendsen, PhD, director of the Cedars-Sinai Regenerative Medicine Institute and a senior author of the study. "In addition to increasing our understanding of this disorder and offering a new pathway to identifying treatments, this study is remarkable because of the extensive interactions between a large group of scientists focused on developing this model. It's a new way of doing trailblazing science."

The Huntington's Disease iPSC Consortium united some of the world's top scientists working on this disease. Cedars-Sinai researchers took skin cells from a several Huntington's patients, including a six-year-old with a severe juvenile form of the disease. They genetically reprogrammed these tissues into induced pluripotent stem cells, which can be made into any type of cell in the body. The cells lines were banked by scientists at Cedars-Sinai and scrutinized by all consortium members for differences that may have led to the disease. These cell lines are now an important resource for Huntington's researchers and have been made available via a National Institutes of Health-funded repository at Coriell Institute for Medical Research in New Jersey.

Huntington's, known to the public, for example, as the cause of folksinger Woody Guthrie's death, typically strikes patients in midlife. It causes jerky, twitching motions, loss of muscle control, psychiatric disorders and dementia; the disease ultimately is fatal. In rare, severe cases, the disorder appears in childhood.

Researchers believe that Huntington's results from a mutation in the huntintin gene, leading to production of an abnormal protein and ultimately cell death in specific areas of the brain that control movement and cognition. There is no cure for Huntington's, nor therapies to slow its progression.

The consortium showed Huntington's cell deficits or how they differ from normal cells, including that they were less likely to survive cultivation in the petri dish. Scientists tried depriving them of a growth factor present around normal cells, or "stressing" them, and found that Huntington's neurons died even faster.

"It was great that these characteristics were seen not only in our laboratory, but by all of the consortium members using different techniques," said Virginia Mattis, a post-doctoral scientist at the Cedars-Sinai Regenerative Medicine Institute and one of the lead authors of the study. "It was very reassuring and significantly strengthens the value of this study."

See the original post here:
Cedars-Sinai researchers, with stem cells and global colleagues, develop Huntingtons research tool

Posted in Stem Cells | Comments Off on Cedars-Sinai researchers, with stem cells and global colleagues, develop Huntingtons research tool

Stem cells help some ailing Houston Zoo creatures

Posted: June 28, 2012 at 5:18 pm

HOUSTON -

Pandu, the 286-pound Malayan tiger stretched out on the gurney in the Houston Zoo's hospital, had bone chips big ones in his right elbow.

Ivy the leopard, being prepped in another room, also needed medical treatment for her limp. The zoo's 68-pound black cat, which had arthroscopic surgery in 2009, was showing signs of pain again in her elbows.

The zoo staff was worried.

"I imagine we are going to end up euthanizing her at some point if it can't be fixed," said Beth Schaefer, the zoo's curator of carnivores and primates.

With two big cats needing attention, surgeon Brian Beale of Gulf Coast Veterinary Specialists and stem-cell specialists at InGeneron Inc. donated their services to treat the animals. While Beale removed bone chips and cleaned the joints during arthroscopic surgery, InGeneron staffers produced stem cells from each animal's body fat.

When the surgeries were complete, Beale injected the stem cells, which had taken about two hours to process for each big cat, into the animals' joints to promote faster healing.

Pandu, always a big baby looking for attention, was moving a bit slowly the day after surgery.

Feisty Ivy pretended nothing was wrong.

A week after the surgery, Houston Zoo veterinarian Lauren Howard says neither animal has suffered complications. Pandu, with mild swelling, was released into his exhibit half-days on Monday.

Follow this link:
Stem cells help some ailing Houston Zoo creatures

Posted in Stem Cells | Comments Off on Stem cells help some ailing Houston Zoo creatures

Regenerative medicine pioneer continues changing lives with first successful laryngotracheal implants

Posted: June 28, 2012 at 5:17 pm

Harvard Bioscience's "InBreath" Bioreactors Used in World's First Successful Regenerated Laryngotracheal Transplants

First Two Transplants Performed in Government-Approved Clinical Trial in Russia

HOLLISTON, Mass., June 26, 2012 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, announces that its "InBreath" bioreactors were used for the world's first and second successful laryngotracheal implants, using synthetic laryngotracheal scaffolds seeded with cells taken from the patients' bone marrow. The surgeries took place at Krasnodar Regional Hospital in Krasnodar, Russia on June 19th and June 21st. The recipients of the implants, Julia T. and Aleksander Z., are recovering well. The implants in the procedures were grown in bioreactors developed by the regenerative medicine device business of Harvard Bioscience.

The transplants, which required more than a half-year of preparation, were performed on the first two patients enrolled in an ongoing clinical trial at Krasnodar Regional Hospital. The Russian Ministry of Health has approved a clinical protocol for an unlimited number of patients in this trial, all of which will involve trachea procedures.

Each bioreactor was specifically adapted by Harvard Bioscience to the clinical requirements for each patient. Each bioreactor was loaded with a synthetic scaffold in the shape of the patient's original organ. The scaffolds were then seeded with the patient's own stem cells. Over the course of about two days, the bioreactor promoted proper cell seeding and development. Because the patients' own stem cells were used, their bodies have accepted the transplants without the use of immunosuppressive drugs.

A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13437

The procedures are the result of a global collaboration involving organizations in the US, Sweden, Russia, Germany, and Italy:

-- The bioreactors were developed, manufactured and prepared by teams at Hugo Sachs Elektronik, a German subsidiary of Harvard Bioscience and at Harvard Bioscience, based in Massachusetts, U.S.A.

-- The scaffolds were created by US-based Nanofiber Solutions.

-- The principal transplant surgeon and main coordinator for both procedures was Dr. Paolo Macchiarini, Professor of Regenerative Surgery at Karolinska Institute in Stockholm.

Read the rest here:
Regenerative medicine pioneer continues changing lives with first successful laryngotracheal implants

Posted in Regenerative Medicine | Comments Off on Regenerative medicine pioneer continues changing lives with first successful laryngotracheal implants

Diabetes Reversal In Mice Via Stem Cells

Posted: June 28, 2012 at 5:16 pm

June 28, 2012

Connie K. Ho for redOrbit.com Your Universe Online

Diabetes is a detrimental disease. In order to combat the illness, University of British Columbia (UBC) researchers conducted a study with an industry partner and discovered that stem cells can reverse Type 1 diabetes in mice.

The discovery leads the way for the development of innovative treatments of diabetes, which is caused by deficient production of insulin by the pancreas. Insulin allows glucose to be held by the bodys muscle, fat, and liver; in turn, its used as fuel for the body. Blindness, heart attack, kidney failure, nerve damage, and stroke are possible consequences of low insulin production. The research by the UBC investigators addressed these various issues. The study was led by Timothy Kieffer, a professor in the Department of Cellular and Physiological Sciences, as well as scientists from BetaLogics, the New Jersey-based division of Janssen Research & Development, LLC.

We are very excited by these findings, but additional research is needed before this approach can be tested clinically in humans, remarked Kieffer, a member of UBCs Life Sciences Institute, in a prepared statement.

The team of investigators is the first to demonstrate that human stem cell transplants can bring back insulin production and reverse diabetes in mice. They were able to re-create the feedback loop that allows insulin levels to automatically increase or decrease based on blood glucose levels. The results from their projects was recently published online on the website of the journal Diabetes.

Following the stem cell transplant, the diabetes mice were slowly taken off insulin, a procedure which was to mirror human clinical condition. Even if they were given copious amounts of sugar, the mice were able to continue healthy blood sugar levels three to four months later. The transplanted cells that were removed from the mice many months after the experiments also showed signs of normal insulin-producing pancreatic cells.

Essentially, the mice were cured of their diabetes by placing the body back in charge of regulated insulin production as it is in healthy, non-diabetics, Kieffer told the Vancouver Sun. It took about four to five months for the [stem] cells to become functional in our experiments and the mice were able to maintain good blood glucose levels even when fed a high-glucose diet, said Kieffer, a UBC professor in the department of cellular and physiological sciences.

Research still needs to be done to finalize details of the approach for diabetes treatment.

The studies were performed in diabetic mice that lacked a properly functioning immune system that would otherwise have rejected the cells. We now need to identify a suitable way of protecting the cells from immune attack so that the transplant can ultimately be performed in the absence of any immunosuppression, explained Kieffer in the statement.

Read more:
Diabetes Reversal In Mice Via Stem Cells

Posted in Diabetes | Comments Off on Diabetes Reversal In Mice Via Stem Cells

Diabetes breakthrough: UBC scientists reverse disease in mice using stem-cell transplants

Posted: June 28, 2012 at 5:15 pm

VANCOUVER -- For the first time ever, University of B.C. scientists have used human embryonic stem cell transplants to reverse Type 1 diabetes in mice with the disease, giving hope to about 300 million people around the world who suffer from the chronic disease.

A 13-member team, whose milestone work is published in the journal Diabetes, shows that after transplantation, the stem cells matured into insulin-secreting, pancreatic beta-cells. The cells automatically sensed blood sugar levels to release the right amount of insulin and a few dozen diabetic mice were gradually weaned off insulin given to them over a period of months.

Insulin is produced by beta-cells to to help the body absorb sugar and use it for energy.

Essentially, the mice were cured of their diabetes by placing the body back in charge of regulated insulin production as it is in healthy, non-diabetics, said lead author Timothy Kieffer.

It took about four to five months for the [stem] cells to become functional in our experiments and the mice were able to maintain good blood glucose levels even when fed a high-glucose diet, said Kieffer, a UBC professor in the department of cellular and physiological sciences.

Type 1 diabetes otherwise known as juvenile diabetes is an autoimmune disease in which a patients immune system kills off insulin-producing cells in the pancreas. About 10 per cent of diabetics are Type 1 and typically, they must inject themselves with insulin or use pumps to control their blood glucose levels.

While pancreatic islet cell transplantation pioneered at the University of Alberta several years ago has been shown to be an effective way of reducing dependence on insulin injections, the treatment is costly and cumbersome as it requires donor cells from cadavers, which are always in short supply. As well, islet cell transplant patients must forever take anti-rejection drugs that can cause organ damage.

In the study methodology, mice were anesthetized and then injected with millions of cells derived from stem cells which were placed under the left kidney area.

Although the research showed that stem cells may one day provide a cure for diabetes, it also revealed hurdles to overcome before agencies like the Food and Drug Administration in the United States or Health Canada can approve the therapy.

For example, some mice developed bone or cartilage in areas where the cells were inserted, an unacceptable side-effect that future experiments must resolve.

View original post here:
Diabetes breakthrough: UBC scientists reverse disease in mice using stem-cell transplants

Posted in Stem Cell Therapy | Comments Off on Diabetes breakthrough: UBC scientists reverse disease in mice using stem-cell transplants

Canadian scientists use stem cells to reverse diabetes in mice

Posted: June 28, 2012 at 5:24 am

VANCOUVER In a world's first, University of B.C. scientists have used human embryonic stem cell transplants to reverse diabetes in mice.

A 13-member team, whose work was published Wednesday in the journal Diabetes, showed that as the stem cells matured into insulin-secreting cells (beta-cells in the pancreas), a few dozen diabetic mice were weaned gradually off insulin over a period of months.

The study, which cost at least $500,000, was funded by the Canadian Institutes of Health Research, the Stem Cell Network of Canada, Stem Cell Technologies of Vancouver, the Juvenile Diabetes Research Foundation and the Michael Smith Foundation of Health Research. About half the research team was comprised of scientists from the New Jersey private research and development arm (BetaLogics Venture) of Janssen Pharmaceuticals.

"It took about four to five months for the (stem) cells to become functional in our experiments and the mice were able to maintain good blood glucose levels even when fed a high-glucose diet," said lead author Timothy Kieffer, a UBC professor in the department of cellular and physiological sciences.

Type 1 otherwise known as juvenile diabetes is an autoimmune disease in which a patient's immune system kills off insulin-producing cells in the pancreas. Typically, patients must inject themselves with insulin or use insulin pumps to control their blood glucose levels.

While pancreatic islet cell transplantation pioneered at the University of Alberta several years ago has been shown to be an effective way of reducing dependence on insulin injections, such treatments are costly and cumbersome since they require cells culled from dead bodies; such cells are always in short supply. As well, islet cell transplant patients must forever take anti-rejection drugs that can cause organ damage.

Although the research showed that stem cells have great potential as a diabetes cure, it also revealed there are still a few pitfalls to overcome before agencies like the Food and Drug Administration in the United States or Health Canada approve such a therapy. Some mice developed bone or cartilage growths in areas where the cells were inserted, an unacceptable side-effect that future experiments must resolve.

Another obstacle is that the mice used in the study weren't typical; they were a special strain, bred to be immuno-compromised so they wouldn't reject the human cells as foreign invaders. Studies are continuing at UBC, in many more mice, to determine the feasibility of encapsulating stem cells in a membrane material that won't be recognized as a foreign body and rejected.

Kieffer said he's extremely encouraged by the fact that the mice not only were weaned off their need for insulin but also lived well and long, even though they were bred to be immune-deficient. Still, he said, researchers must find ways to fine-tune the approach so that cells don't evolve into something other than what's desired.

In the early stages of the experiment, some mice developed fluid-filled cysts, a problem that was rectified in the laboratory with a cell culture medium change.

See more here:
Canadian scientists use stem cells to reverse diabetes in mice

Posted in Stem Cell Videos | Comments Off on Canadian scientists use stem cells to reverse diabetes in mice

Page 2,709«..1020..2,7082,7092,7102,711..2,7202,730..»